Premium
Dosage of colloidal bismuth subcitrate in duodenal ulcer healing and clearance of Campylobacter pylori
Author(s) -
COGHLAN J.,
HUTCHINSON L.,
GILLIGAN D.,
McKENNA D.,
KEANE C.,
SWEENEY E.,
O'MORAIN C.
Publication year - 1990
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1990.tb00448.x
Subject(s) - medicine , gastroenterology , campylobacter , endoscopy , regimen , gastritis , biopsy , duodenal ulcer , antrum , spirillaceae , metronidazole , surgery , helicobacter pylori , antibiotics , stomach , genetics , bacteria , biology , microbiology and biotechnology
SUMMARY Sixty consecutive patients with endoscopically proven duodenal ulcers were given colloidal bismuth subcitrate tablets either as 120 mg q.d.s. or 240 mg b.d., in a randomized single‐blind study. The efficacy of each regimen was determined by endoscopic examination and antral biopsy at 4 weeks; if the ulcer remained unhealed, treatment was continued and endoscopy repeated at 8 weeks. The ulcer‐healing efficacy of the two regimens was identical; however, in the four times daily group only 27% remained Campylobacter pylori positive after 8 weeks of treatment compared with 58% of the twice‐daily group. Similarly, only 21% of twice daily patients were free of histological gastritis compared with 42% of the four times daily patients.